79955.1 TENT

13510CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

olicant:

LEAKE et al.

Examiner:

To be assigned

Serial No.:

10/613077

Group Art Unit:

1623

Filed:

July 1, 2003

For:

Stabilized Polynucleotides for Use in RNA Interference

Customer No.:

23719

Kalow & Springut LLP

488 Madison Avenue, 19th Floor New York, New York 10022

January 6, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wishes to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of cited references are enclosed). As to any reference supplied, Applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants' duty to disclose all information of which they are aware and believe relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

Signature)

Applicant: LEAKE et al. Serial No.: 10/613077 Filed: July 1, 2003 January 6, 2005

Supplemental Information Disclosure Statement

Page 2 of 3

I. U.S. PATENT DOCUMENTS

Patent No. 20040102408A1	<u>Date</u> May 27, 2004	Title Method and medicament for inhibiting the expression of a given gene
200040072779A1	April 15, 2004	Method and medicament for inhibiting the expression of a given gene
20040053875A1	March 18, 2004	Method and medicament for inhibiting the expression of a given gene
5,023,243	July 11,1991	Oligonucletotide therapeutic agent and method of making same
6,005,094	December 21,1999	Oligonucleotide analogues having improved stability at acid PH.
5,919,619	July 6,1999	Oligonucleotide therapeiutic agent and methods of making same
5,912,339	June 15,1999	Oligonucleoside alkyl or arylphoshonate derivatives capable of cross linking with or cleaving nucleic acids

II. FOREIGN PATENT DOCUMENTS

Publication No.	Country	Publication Date
WO 99/32619	WIPO	1 July 1999
WO 01/75164 A2	WIPO	11 October 2001
WO 02/44321 A2	WIPO	6 June 2002
EP 1 144 623 B1	EPO	17 October 2001

Applicant: LEAKE et al. Serial No.: 10/613077

Filed: July 1, 2003 January 6, 2005

Supplemental Information Disclosure Statement

Page 3 of 3

III. NON PATENT PUBLICATIONS

Applicants have submitted European Patent Application No. 00910510.7, which was published in German. For the convenience of the Examiner, Applicants have also listed herein the following applications, which are English language U.S. patent publications that claim priority to EP 1 144 623 B1: US 20040102408A1, US 20040072779A1, and US 20040053875A1.

Because no action has been taken on the merits, Applicants submit that no fee is due at this time. However, if a fee is deemed necessary, please charge Deposit Account No. 11-0171.

Respectfully submitted,

Tor Smeland

Registration No.: 43,131 Attorney for Applicant

Kalow & Springut LLP (212) 813-1600

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Stitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/613,077		
Filing Date	July 1, 2003	_	
First Named Inventor	LEAKE et al.		
Art Unit	1623		
Examiner Name	To be assigned		
Attorney Docket Number	13510CIP		

			U. S. PATENT	DOCUMENTS	11 126
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (§ known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2004-0102408 A1	May 27, 2004	KREUTZER et al	
		us- 2004-0072779 A1	April 15, 2004	KRUETZER et al	
	-	us- 2004-0053875 A1	Mar. 18, 2004	KRUETZER et al	
		us- 5,023,243	July 11, 1991	TULLIS	
		US- 6,005,094	Dec.21,1999	SIMON et al	
		∪s- 5,919,619	July 6, 1999	TULLIS	
	 	us- 5,912,339	June 15, 1999	MILLER et al	
	+	US-			
		US-			
	<u> </u>	US-			
	1	US-			
	+	US-			
	+	US-			
	-	US-			
		US-			
		US-			
		US-			
	\top	US-			
	1	US-			

FOREIGN PATENT DOCUMENTS Publication Name of Patentee or Pages, Columns, Lines,						
Examiner Initials*	Cite No.1	Foreign Patent Document	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 99/32619	1July 1999			T
		WO 01/75164 A2		TUSCHL et al		十
		WO 02/44321 A2	6 June 2002	TUSCHL et al		\vdash
		EP 1144 623 B1	17 Oct. 2001	KREUTZER		十
						╆
	1					

l		
	Date	
Examiner	Considered	
Signature	 line through	citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). See Kinds Codes of Considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.